This appraisal has formally started now, in line with the anticipated regulatory timelines. However, the company that markets lutetium-177 DOTATATE has informed us that they are not able to provide an evidence submission for this appraisal. NICE will therefore suspend this appraisal with immediate effect.
|
Status
|
Suspended
|
| Process |
STA pre-2018
|
| ID number |
857
|
Project Team
Email enquiries
| Evidence Review Group / Assessment Group |
Liverpool Reviews and Implementation Group, University of Liverpool |
Consultees
| Companies sponsors |
Imaging Equipment (lutetium-177 DOTATATE) |
| Others |
Department of Health |
| |
NHS England |
| |
Welsh Government |
| Professional groups |
British Nuclear Medicine Society |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiographers |
| |
UK and Ireland Neuroendocrine Tumour Society (UKI NETS) |
Commentators
| Comparator companies |
Hospira UK - CAU not returned, not participating |
| |
Ipsen - CAU not returned, not participating |
| |
Novartis Pharmaceuticals UK - CAU not returned, not participating |
| |
Sun Pharmaceuticals UK - CAU not returned, not participating |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |